drugset / Trial / NCT07294508
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Timeline
- Start
- 2026-02-27
- Primary completion
- 2028-01-15
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | HLX22 | Monoclonal antibody | — | — |
| Subject | HLX87 | Other / unclassified | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Comparator | T-Dxd | Unknown | — | — |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |